Neurocrine Biosciences Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative treatments for neurological and endocrine-related disorders. ... Neurocrine Biosciences Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative treatments for neurological and endocrine-related disorders. The primary function of Neurocrine is to address unmet medical needs within these specialized fields through its research and development efforts. The company is well-known for its product Ingrezza, a treatment for tardive dyskinesia, a movement disorder, as well as Orilissa for endometriosis pain, developed in partnership with AbbVie. Neurocrine Biosciences significantly impacts the healthcare and pharmaceutical industries by advancing therapies for complex conditions that lack effective treatments. The company maintains a strong presence in the market through its robust pipeline of potential therapies, targeting diseases like Parkinson’s and congenital adrenal hyperplasia. Founded in 1992 and headquartered in San Diego, California, Neurocrine continues to leverage cutting-edge science to improve patient outcomes, underlining its role as a leader in the biopharmaceutical sector dedicated to neurological and endocrine health.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Energy Management data not yet covered for Neurocrine Biosciences

We have not yet reviewed Neurocrine Biosciences's disclosures for Energy Management data.

If this data is relevant to your work, you can submit a data coverage request and our team will investigate the company's disclosures and capture the data if available.

Would you like us to review Neurocrine Biosciences's data?

Create a free Tracenable account to signal interest in having our team review data for Neurocrine Biosciences.

Legal Center Contact Us